CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,753 enrolled
Drug / intervention
Donor Search Prognosis Scoreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03904134
NCT03904134N/ACompleted

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

Center for International Blood and Marrow Transplant Research·interventional·Posted Apr 5, 2019·Updated Jan 5, 2026

In Brief

A clinical study evaluating Donor Search Prognosis Score for Acute Myeloid Leukemia and 6 related conditions. Completed, enrolled 1,753 participants across 52 sites.

Detailed Summary

The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not available versus proceeding directly to an alternative donor transplant will result in better survival for allogeneic transplant recipients within 2 years after study enrollment.

Study Details

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 5, 2019
Enrollment StartJun 14, 2019
Primary CompletionJan 6, 2025
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 7.2 years ago

Interventions

Donor Search Prognosis Scoreother

Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.